GO:0004852 uroporphyrinogen-III synthase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004852 describes the enzymatic activity that converts hydroxymethylbilane into uroporphyrinogen III and water, a key step in heme biosynthesis.
• The reaction is catalyzed by uroporphyrinogen III synthase (UROS), a cytosolic enzyme that cyclizes the linear tetrapyrrole hydroxymethylbilane.
• Loss-of-function mutations in UROS cause congenital erythropoietic porphyria (CEP), a rare autosomal recessive disorder with severe cutaneous photosensitivity.
• UROS is highly conserved across species, and its crystal structure has been solved for both human and bacterial enzymes.
• Knock-in mouse models carrying human CEP mutations recapitulate the disease phenotype, including light-induced skin lesions.
• Studying GO:0004852 helps researchers understand heme biosynthesis, porphyria pathogenesis, and potential therapeutic targets.
Description
Uroporphyrinogen-III synthase activity (GO:0004852) is a molecular function that catalyzes the cyclization of hydroxymethylbilane to uroporphyrinogen III, a critical step in the heme biosynthetic pathway. This enzymatic activity is essential for the production of heme, which is required for oxygen transport, electron transfer, and various metabolic processes. The enzyme responsible, uroporphyrinogen III synthase (UROS), is a cytosolic protein that ensures the correct isomerization of the linear tetrapyrrole, preventing the accumulation of toxic intermediates. Researchers study this activity to understand porphyrin metabolism and related disorders such as congenital erythropoietic porphyria. The reaction is unique because it involves an intramolecular rearrangement without the need for cofactors, making it a fascinating target for mechanistic enzymology.
uroporphyrinogen-III synthase activity At A Glance
| GO ID | GO:0004852 |
|---|---|
| GO term | uroporphyrinogen-III synthase activity |
| Ontology | molecular_function |
| Synonym | uroporphyrinogen III cosynthase activity; hydroxymethylbilane hydro-lyase (cyclizing) activity; porphobilinogenase activity; uroporphyrinogen isomerase activity |
| Major function | Catalyzes the cyclization of hydroxymethylbilane to uroporphyrinogen III and water |
| Reaction | hydroxymethylbilane = H2O + uroporphyrinogen III |
| Pathway | Heme biosynthesis |
| Enzyme | Uroporphyrinogen III synthase (UROS) |
| Cofactors | None required |
What Is GO:0004852?
Uroporphyrinogen-III synthase activity (GO:0004852) is defined as the catalysis of the reaction: hydroxymethylbilane = H2O + uroporphyrinogen III. In other words, it is the enzyme activity that converts the linear tetrapyrrole hydroxymethylbilane into the cyclic tetrapyrrole uroporphyrinogen III, releasing a molecule of water. This activity is synonymous with uroporphyrinogen III cosynthase, uroporphyrinogen isomerase, and porphobilinogenase, reflecting its role in the fourth step of heme biosynthesis.
Why Is uroporphyrinogen-III synthase activity Important in Cell Biology?
Uroporphyrinogen-III synthase activity is essential for heme biosynthesis, as it catalyzes the formation of uroporphyrinogen III, the precursor for all downstream porphyrins and heme. Defects in this activity lead to congenital erythropoietic porphyria, a debilitating disease characterized by severe photosensitivity and anemia. Understanding this enzymatic step provides insights into porphyrin metabolism and offers potential therapeutic targets for porphyrias and other disorders of heme synthesis.
• Critical for heme biosynthesis and oxygen transport.
• Mutations cause congenital erythropoietic porphyria (CEP).
• Enzyme is conserved from bacteria to humans.
• No cofactors required, making it a model for mechanistic studies.
• Knock-in mouse models mimic human disease for research.
• Target for gene therapy and small-molecule chaperones.
• Involved in regulation of porphyrin biosynthesis.
• Provides insights into enzyme evolution and catalysis.
Molecular Mechanism of uroporphyrinogen-III synthase activity
Substrate Binding and Recognition
In simple terms: The enzyme grabs the linear molecule hydroxymethylbilane and holds it in place.
Uroporphyrinogen III synthase binds its substrate, hydroxymethylbilane, a linear tetrapyrrole. NMR-based mapping of the active site of human UROS revealed key residues involved in substrate binding, including arginine and lysine residues that interact with the carboxylate groups of the substrate. The enzyme recognizes the linear tetrapyrrole and positions it for cyclization.
Cyclization and Isomerization
In simple terms: The enzyme bends the linear molecule into a ring and rearranges it to form uroporphyrinogen III.
The catalytic mechanism involves an intramolecular rearrangement where the linear hydroxymethylbilane is cyclized to form the asymmetric uroporphyrinogen III. This step is unique because it does not require cofactors or metal ions; instead, it relies on precise acid-base chemistry within the active site. The reaction releases a water molecule and produces uroporphyrinogen III, the first cyclic tetrapyrrole in the heme pathway.
Product Release and Channeling
In simple terms: The newly formed ring is released to continue down the heme production line.
After cyclization, uroporphyrinogen III is released from the enzyme. In vivo, it is likely channeled to the next enzyme in the pathway, uroporphyrinogen decarboxylase, to prevent spontaneous oxidation. The efficient release and downstream processing ensure that heme synthesis proceeds without accumulation of toxic intermediates.
Structural Basis of Catalysis
In simple terms: The enzyme's 3D shape reveals how it performs the reaction.
Crystal structures of human UROS and bacterial homologs have provided insights into the catalytic mechanism. The human enzyme is a monomer with a central beta-sheet flanked by alpha-helices, and the active site is located in a cleft that accommodates the substrate. The bacterial enzyme from Pseudomonas syringae shows a similar fold, indicating evolutionary conservation. These structures reveal that the enzyme uses a conserved aspartate residue as a general acid/base during catalysis.
Key Genes Involved in GO:0004852 uroporphyrinogen-III synthase activity
The following genes and proteins are directly involved in uroporphyrinogen-III synthase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| UROS | Encodes uroporphyrinogen III synthase, the enzyme catalyzing GO:0004852 | Mutations cause CEP; target for gene therapy |
| HMBS | Encodes hydroxymethylbilane synthase, which produces the substrate hydroxymethylbilane | Defects cause acute intermittent porphyria |
| UROD | Encodes uroporphyrinogen decarboxylase, the next enzyme in heme biosynthesis | Defects cause porphyria cutanea tarda |
| CPOX | Encodes coproporphyrinogen oxidase, involved in later heme synthesis steps | Defects cause hereditary coproporphyria |
| PPOX | Encodes protoporphyrinogen oxidase, involved in later heme synthesis steps | Defects cause variegate porphyria |
| FECH | Encodes ferrochelatase, which inserts iron into protoporphyrin IX to form heme | Defects cause erythropoietic protoporphyria |
| ALAS1 | Encodes delta-aminolevulinate synthase 1, the rate-limiting enzyme of heme synthesis in non-erythroid cells | Regulated by heme and drugs |
| ALAS2 | Encodes delta-aminolevulinate synthase 2, the erythroid-specific isoform | Mutations cause X-linked sideroblastic anemia |
| GATA1 | Transcription factor regulating erythroid-specific genes including UROS | Involved in erythroid differentiation |
| ABCG2 | Transporter that may influence porphyrin accumulation | Modifies CEP phenotype |
| HRI | Heme-regulated inhibitor kinase, senses heme levels | Regulates translation in erythroid cells |
| BACH1 | Transcription factor repressing heme oxygenase-1 and globin genes | Regulates heme homeostasis |
| NCOA4 | Selective autophagy receptor for ferritin, affects iron availability | Modulates heme synthesis |
| SLC25A38 | Mitochondrial glycine transporter, involved in heme synthesis | Mutations cause sideroblastic anemia |
| FTH1 | Ferritin heavy chain, iron storage | Affects iron availability for heme |
| FTL | Ferritin light chain, iron storage | Affects iron availability for heme |
| TFRC | Transferrin receptor, iron uptake | Regulates iron for heme synthesis |
| ISCU | Iron-sulfur cluster assembly, related to heme synthesis | Mutations cause sideroblastic anemia |
How Is uroporphyrinogen-III synthase activity Regulated?
Uroporphyrinogen III synthase activity is regulated at multiple levels. Transcription of the UROS gene is controlled by erythroid-specific transcription factors such as GATA1, which coordinates heme synthesis with globin production during erythropoiesis. Additionally, the enzyme's activity can be influenced by the availability of its substrate, hydroxymethylbilane, which is produced by hydroxymethylbilane synthase (HMBS). In non-erythroid cells, heme biosynthesis is regulated by the rate-limiting enzyme ALAS1, which is feedback-inhibited by heme. Post-translational modifications of UROS have not been extensively studied, but its stability may be affected by mutations that cause misfolding and rapid degradation.
uroporphyrinogen-III synthase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| UROS | Congenital erythropoietic porphyria | UROS knockout or knock-in mice |
| HMBS | Acute intermittent porphyria | Hmbs knockout mice |
| UROD | Porphyria cutanea tarda | Urod knockout mice |
| FECH | Erythropoietic protoporphyria | Fech knockout mice |
| ALAS2 | X-linked sideroblastic anemia | Alas2 knockout mice |
Congenital Erythropoietic Porphyria (CEP)
Congenital erythropoietic porphyria (CEP) is an autosomal recessive disorder caused by mutations in the UROS gene, leading to deficient uroporphyrinogen III synthase activity. The disease is characterized by severe cutaneous photosensitivity, blistering, scarring, and hemolytic anemia. Accumulation of uroporphyrin I and coproporphyrin I in erythrocytes, plasma, and urine leads to tissue damage upon light exposure. Treatment options include bone marrow transplantation and gene therapy, but management remains challenging.
Mouse Models of CEP
Knock-in mouse models carrying human CEP mutations have been generated to study the disease. These mice exhibit the characteristic light-induced cutaneous lesions, anemia, and porphyrin accumulation, mimicking the human phenotype. Such models are valuable for testing novel therapies, including gene editing and small-molecule chaperones.
Other Porphyrias
While CEP is the primary disease linked to UROS mutations, other porphyrias result from defects in different heme synthesis enzymes. For example, acute intermittent porphyria is caused by HMBS mutations, and porphyria cutanea tarda by UROD mutations. Understanding the role of UROS in the pathway helps delineate the specific contributions of each enzyme to disease.
From uroporphyrinogen-III synthase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of UROS loss on heme synthesis? | UROS knockout cell lines (e.g., K562) |
| How do specific UROS mutations affect enzyme activity? | Point-mutation knock-in models (e.g., C73R) |
| Can gene therapy rescue CEP phenotype? | Knock-in mouse model with human UROS mutation |
| Where is UROS localized in cells? | Tagged knock-in with fluorescent protein |
| What is the effect of UROS overexpression? | Overexpression cell lines |
| Can small molecules stabilize mutant UROS? | Patient-derived fibroblasts or iPSCs |
How to Study the uroporphyrinogen-III synthase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | Conversion of hydroxymethylbilane to uroporphyrinogen III | Diagnosis of CEP, mutant characterization |
| X-ray crystallography | Three-dimensional structure of UROS | Mechanistic studies, drug design |
| NMR spectroscopy | Active site mapping, substrate binding | Understanding catalysis |
| Whole-exome sequencing | UROS mutations | Genetic diagnosis of CEP |
| CRISPR-Cas9 editing | Introduction of specific mutations | Creating disease models |
| Mass spectrometry | Porphyrin intermediates | Metabolic profiling |
| HPLC | Porphyrin isomers | Diagnosis and monitoring |
| Western blot | UROS protein levels | Expression analysis |
Enzymatic Activity Assays
Uroporphyrinogen III synthase activity can be measured using spectrophotometric or fluorometric assays that detect the formation of uroporphyrinogen III. Typically, hydroxymethylbilane is generated in situ by porphobilinogen deaminase, and the product is oxidized to uroporphyrin I and III isomers for quantification. These assays are essential for diagnosing CEP and characterizing mutant enzymes.
Structural Biology
X-ray crystallography and NMR spectroscopy have been used to determine the structure of UROS and map its active site. The crystal structure of human UROS revealed a unique fold and identified key catalytic residues. NMR-based mapping provided insights into substrate binding and conformational changes. These methods are crucial for understanding the mechanism and for structure-based drug design.
Genetic and Genomic Approaches
Next-generation sequencing, including whole-exome and targeted panel sequencing, is used to identify UROS mutations in patients with CEP. CRISPR-Cas9 genome editing enables the creation of isogenic cell lines and animal models carrying specific mutations. These approaches help establish genotype-phenotype correlations and test therapeutic strategies.
Metabolic Profiling
Mass spectrometry and HPLC are used to quantify porphyrin intermediates in cells and tissues. In CEP, elevated uroporphyrin I and coproporphyrin I are diagnostic. Metabolomic profiling can also reveal broader effects on heme synthesis and iron metabolism.
How CRISPR Can Be Used to Study GO:0004852 uroporphyrinogen-III synthase activity
Knockout
CRISPR-Cas9 knockout of UROS in cell lines such as K562 or HEK293 can abolish uroporphyrinogen III synthase activity, leading to accumulation of uroporphyrin I and reduced heme synthesis. These models are useful for studying the consequences of enzyme deficiency and for testing rescue strategies.
Point Mutation
Point mutations identified in CEP patients, such as C73R, can be introduced into the endogenous UROS locus using CRISPR-Cas9 and homology-directed repair. These isogenic models allow precise assessment of mutation effects on enzyme activity, stability, and protein folding.
Knock-in
Knock-in mice carrying human UROS mutations, such as the C73R variant, have been generated using CRISPR-Cas9. These mice develop a phenotype resembling human CEP, including photosensitivity and anemia, providing a valuable platform for preclinical testing of gene therapy and pharmacological chaperones.
Overexpression
Overexpression of wild-type or mutant UROS in cell lines can be achieved by CRISPR activation (CRISPRa) or lentiviral transduction. Overexpression studies help determine the effects of increased enzyme levels on heme synthesis and porphyrin accumulation, and can be used to produce recombinant enzyme for structural and biochemical studies.
How EDITGENE Supports uroporphyrinogen-III synthase activity Research
Researchers studying uroporphyrinogen-III synthase activity-related genes often need to determine whether a candidate gene is causally involved in heme biosynthesis or porphyria pathogenesis. EDITGENE provides comprehensive CRISPR-based services to create precise cell and animal models, enabling functional validation of UROS and related genes.
Contact EDITGENE today to design your custom CRISPR model for uroporphyrinogen-III synthase activity research.
Frequently Asked Questions About uroporphyrinogen-III synthase activity
What is uroporphyrinogen-III synthase activity?
Uroporphyrinogen-III synthase activity (GO:0004852) is the enzymatic conversion of hydroxymethylbilane to uroporphyrinogen III and water, a key step in heme biosynthesis.
What genes are involved in uroporphyrinogen-III synthase activity?
The primary gene is UROS, which encodes the enzyme uroporphyrinogen III synthase. Other genes in the heme pathway include HMBS, UROD, and FECH.
What diseases are associated with uroporphyrinogen-III synthase activity?
Deficiency causes congenital erythropoietic porphyria (CEP), a rare disorder with severe skin photosensitivity and anemia.
How is uroporphyrinogen-III synthase activity measured?
It is measured using enzyme assays that detect the formation of uroporphyrinogen III, often coupled with porphobilinogen deaminase and spectrophotometric detection.
What is the structure of uroporphyrinogen III synthase?
The human enzyme is a monomer with a central beta-sheet and alpha-helices. Crystal structures have revealed the active site and catalytic residues.
Are there mouse models for UROS deficiency?
Yes, knock-in mice carrying human CEP mutations develop a phenotype similar to human CEP, including light-induced skin lesions.
Can CRISPR be used to study UROS function?
Yes, CRISPR-Cas9 can create UROS knockout, point mutation, and knock-in models to study enzyme function and disease mechanisms.
What are the synonyms for uroporphyrinogen-III synthase activity?
Synonyms include uroporphyrinogen III cosynthase activity, hydroxymethylbilane hydro-lyase (cyclizing) activity, porphobilinogenase activity, and uroporphyrinogen isomerase activity.
Is uroporphyrinogen III synthase conserved across species?
Yes, the enzyme is highly conserved from bacteria to humans, as shown by crystal structures of human and Pseudomonas syringae enzymes.
What is the reaction catalyzed by uroporphyrinogen III synthase?
The reaction is: hydroxymethylbilane = H2O + uroporphyrinogen III.
Conclusion
Uroporphyrinogen-III synthase activity (GO:0004852) is a fundamental enzymatic step in heme biosynthesis, catalyzing the cyclization of hydroxymethylbilane to uroporphyrinogen III. Its deficiency leads to congenital erythropoietic porphyria, a severe disorder with limited treatment options. Research into this enzyme's mechanism, structure, and regulation has been greatly advanced by CRISPR-based models and structural biology. EDITGENE provides a suite of services to support functional studies of UROS and related genes, from knockout and point mutation models to library screening and bioinformatics.
References
- 1. To-Figueras J et al.. 2024. Congenital erythropoietic porphyria.. Liver Int 44(8):1842-1855 PMID: 38717058
- 2. Cunha L et al.. 2008. Human uroporphyrinogen III synthase: NMR-based mapping of the active site.. Proteins 71(2):855-73 PMID: 18004775
- 3. Tsai SF et al.. 1988. Human uroporphyrinogen III synthase: molecular cloning, nucleotide sequence, and expression of a full-length cDNA.. Proc Natl Acad Sci U S A 85(19):7049-53 PMID: 3174619
- 4. Bishop DF et al.. 2006. Uroporphyrinogen III synthase knock-in mice have the human congenital erythropoietic porphyria phenotype, including the characteristic light-induced cutaneous lesions.. Am J Hum Genet 78(4):645-58 PMID: 16532394
- 5. Omata Y et al.. 2004. Purification and characterization of human uroporphyrinogen III synthase expressed in Escherichia coli.. J Biochem 136(2):211-20 PMID: 15496592
- 6. Tsai SF et al.. 1987. Purification and properties of uroporphyrinogen III synthase from human erythrocytes.. J Biol Chem 262(3):1268-73 PMID: 3805019
- 7. Mathews MA et al.. 2001. Crystal structure of human uroporphyrinogen III synthase.. EMBO J 20(21):5832-9 PMID: 11689424
- 8. Peng S et al.. 2011. Crystal structure of uroporphyrinogen III synthase from Pseudomonas syringae pv. tomato DC3000.. Biochem Biophys Res Commun 408(4):576-81 PMID: 21527255
